An interventional study of Ultrahypofractionated RT+Relugolix in Prostate Cancer (Adenocarcinoma), sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Azienda Ospedaliero-Universitaria Careggi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 339 studies in Prostatic Neoplasms with a site in Italy — 94 open to participants now, 143 under way, 36 of them phase 3. Prostatic Neoplasms · Italy.
Among the 339 studies in Prostatic Neoplasms with a site in Italy, this one is the 195th largest by planned enrollment of the 244 interventional ones that give a count, is one of 31 that started in 2025, is one of 57 with no phase, reaches primary completion later than 79 of the 142 other live ones, and was the 304th registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →94 of the 339 studies in Prostatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Niguarda Hospital · Sites in Italy
Ages 18–85 · Men only
AstraZeneca · Sites in Italy, United States, Austria and 18 more countries
Ages 18+ · Men only
Istituto Clinico Humanitas · Sites in Italy
Ages 18+ · Men only
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Sites in Italy, France, Germany and 2 more countries
Ages 18+ · Men only
AstraZeneca · Sites in Italy, United States, Australia and 4 more countries
Ages 18–99 · Men only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
339 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 70 · Phase 3 105 · Phase 4 8
First in 1992; this study’s year is marked. 31 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 73 is above the median of 60 across 5,354 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 220 across the 244 interventional studies, 280 across the 93 observational. Of the 166 that completed or were terminated, 68 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 339 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliero-Universitaria Careggi is the lead sponsor of 78 studies on the registry; 23 are open to participants now.
Azienda Ospedaliero-Universitaria Careggi has 6 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
35 of the studies in Prostatic Neoplasms with a site in Italy that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT06717711Phase 3Regina Elena Cancer InstituteLow-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers | 2027-02-28 |
| NCT06122584Phase 3ABX advanced biochemical compounds GmbHDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | 2027-03 |
| NCT05794906Phase 3BayerA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | 2027-07-30 |
Add all 35 to your calendar (.ics) → With an account.
Among the 339 studies in Prostatic Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective evidence is needed in order to assess if concomitant treatment with short course ADT with relugolix and RT may obtain the same disease control benefit if compared to historical data related to standard ADT with LH- RH analogues. With this purpose, we designed an interventional trial aimed to evaluate rate of complete biochemical response in an homogeneous cohort of patients affected by intermediate risk localized prostate cancer undergoing prostate radiotherapy+short course oral relugolix.
This is a Prospective, no-profit, single arm phase II, interventional multicentric trial aimed to evaluate the effectiveness of concomitant prostate RT and short course oral Relugolix if compared to literature data related to standard prostate RT associated with standard ADT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with ultrahypofractionated prostate radiotherapy for a total dose of 36.25 Gy in 5 fractions, 7.25 Gy each, every other day. Concomitant treatment with oral Relugolix will be administered.
Other: Ultrahypofractionated RT+Relugolix
Patients will be treated with ultrahypofractionated prostate radiotherapy for a total dose of 36.25 Gy in 5 fractions, 7.25 Gy each, every other day. Concomitant treatment with oral Relugolix will be administered.
Biochemical response
To assess rate of complete biochemical response after 6 months of treatment, defined as PSA \<0.5 ng/ml
Time frame: 6 months from the last patient enrollment
Biochemical relapse free survival (BRFS) at 2 years
Biochemical relapse free survival (BRFS) at 2 years after end of radiotherapy. Biochemical relapse will be defined as a rise by 2 ng/mL or more above the nadir PSA according to RTOG- ASTRO Phoenix Consensus Conferenc
Time frame: 2 years after last patient enrollment
testosterone recovery at 90 days from the end of ADT treatment
Rate of patients with testosterone recovery at 90 days from the end of ADT treatment
Time frame: 90 days from the last patient enrollment
Non pathological fracture at 2 years
Rate of patients experiencing non pathological fracture at 2 years
Time frame: 2 years after last patient enrollment
cardiovascular events at 48 weeks (myocardial infarction and stroke)
Rate of cardiovascular events at 48 weeks (myocardial infarction and stroke)
Time frame: 48 weeks after last patient enrollment
Plan to share: No — IPD will be maintained in a local data repository
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 24 months is below that.
Counting every sponsor, half of 1,158 studies reached it within 43 months; a quarter within 22 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria Careggi